SK bioscience announced on the 17th that it has submitted a clinical trial plan for its new flu vaccine candidate 'NBP607B' to the Ministry of Food and Drug Safety. The flu vaccine Skycellflu has applied an immune enhancer to increase its preventive effect. The clinical trials will be conducted on elderly individuals both domestically and internationally. It will evaluate immunogenicity and safety and confirm interim results by 2027. The company noted, "If successful in vaccine development, we will utilize it as a platform."
Daewoong Pharmaceutical announced on the 17th that it has unveiled 'MobiCare Refresh' in collaboration with Seers Technology. The company collected MobiCare via delivery, cleaned, inspected, and reused it. MobiCare is a wearable electrocardiogram device. The 19g wireless product can capture abnormal heart signals.
Hyundai Pharm announced on the 17th that its 'USP1 inhibitor' has been selected for a drug development ecosystem project led by the National New Drug Development Institute. The USP1 inhibitor is under development as a next-generation anti-cancer drug that selectively eliminates cancer cells. Hyundai Pharm will receive support for the entire drug development cycle.
HLB Global announced on the 17th that it has signed a business agreement with Professor Dennis Hong of the University of California, Los Angeles to develop artificial intelligence (AI) medical and daily assistant robots. Professor Dennis Hong is a world-renowned roboticist. HLB Global is enhancing rehabilitation and exercise assistive robots, such as strength-assist suits. The demonstration and advancement of the robots will be led by Professor Dennis Hong.
GC Biopharma announced on the 17th that its U.S. subsidiary, GC BioPharma USA, presented research results on the viscosity of immunoglobulin preparations at the '2025 International Society on Thrombosis and Haemostasis' held in the U.S. Immunoglobulin preparations are used for treating immune diseases. It is known to increase blood viscosity after administration, thereby raising the risk of thromboembolism. The company measured the viscosity of five types of immunoglobulin preparations at various temperatures. All products showed a tendency for viscosity to decrease as temperature increased.
Daewon Pharmaceutical announced on the 17th that it has published its '2024-2025 Sustainability Management Report.' The company plans to establish carbon neutrality goals and expand eco-friendly processes. It aims to strengthen its sustainable management system.
Hallym University Sacred Heart Hospital announced on the 17th that it will add a third hyperbaric oxygen therapy chamber. Hyperbaric oxygen therapy involves inhaling 100% high-purity oxygen through a mask for a certain period. It is beneficial for burns, carbon monoxide poisoning, decompression sickness, and other sudden accidents. With this addition, 36 patients can undergo treatment simultaneously.
Trioer announced on the 17th that it recently secured a Series B investment worth 22.5 billion won. Trioer is developing Trocad and Trosig. Trocad is an antibody platform that helps specifically target and attack cancer cells. Trosig improves drug delivery, potentially enhancing the efficacy of antibody-drug conjugates (ADCs), according to the company.